Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 µM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-alpha agonist. It inhibits the activation of TLR4-mediated NF-kappaB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-alpha. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation[1][2][3][4][5][6][7].
Molecular Weight:
1047.23
Purity:
99.88
CAS Number:
[94987-08-3]
Formula:
C52H86O21
Target:
Apoptosis,Autophagy,Keap1-Nrf2,NF-kappaB,NOD-like Receptor (NLR),PPAR,Pyroptosis,Reactive Oxygen Species (ROS),Sirtuin,Toll-like Receptor (TLR)
Application Notes:
MCE Product type: Natural Products
* VAT and and shipping costs not included. Errors and price changes excepted
